Philip Morris stock rating reiterated at Buy by Stifel on European growth

Stifel has reiterated its Buy rating and $186 price target for Philip Morris International, citing the company's robust 65.68% gross profit margins and 52.89% six-month return, alongside its strategic focus on multi-category smoke-free products. This strategy, particularly in Europe and with IQOS/ZYN expansion, underpins the reaffirmed 2025 profit forecast, though InvestingPro data suggests the stock is currently overvalued despite consistent dividend increases and strong analyst support from firms like BofA.

Analysis

Philip Morris International is receiving strong endorsements from analysts, with Stifel reiterating a Buy rating and a $186 price target, and BofA Securities increasing its target to $200. This bullish sentiment is underpinned by the company's successful pivot to a multi-category smoke-free product strategy, encompassing IQOS, VEEV, and ZYN pouches. Europe is a pivotal growth engine, projected to contribute approximately one-third of smoke-free growth through 2026. The company's financial health is robust, evidenced by industry-leading gross profit margins of 65.68% and a 17-year track record of consecutive dividend increases. Management has reaffirmed its 2025 profit forecast with an expected EPS between $7.01 and $7.14, reflecting confidence in its strategy and a currency-neutral growth outlook of 10.5% to 12.5%. However, this positive outlook is tempered by valuation concerns. After a 52.89% return over the past six months, the stock is trading near its 52-week high, and InvestingPro analysis suggests it is currently overvalued. This mixed view is echoed by UBS, which maintains a Neutral rating with a $170 price target, despite noting improvements in the U.S. ZYN market. Recent regulatory actions, such as the seizure of unauthorized e-cigarettes by the FDA, could serve as a tailwind by reducing illicit competition.

Key Decisions for Investors

• Given strong analyst support and reaffirmed corporate guidance, investors may view PM as a core holding for exposure to the next-generation products transformation, but should be mindful of the high valuation.
• Potential investors should weigh the bullish growth narrative, driven by the multi-category strategy in Europe and U.S. expansion, against the risk that the stock is considered overvalued after its recent run-up.
• Monitor the U.S. market performance of IQOS and ZYN closely, as successful execution in this region is a key catalyst cited by analysts and is critical for justifying the current share price and achieving 2025 targets.
• Consider the recent regulatory crackdown on illicit products as a positive external factor that could strengthen Philip Morris's market position and reduce competitive pressures from non-compliant entities.